STAT+: Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
Category: Life Sciences
STAT+: Eli Lilly raises earnings guidance as Zepbound sales beat expectations
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of…
.jpg)
What we’re starting to learn about H5N1 in cows, and the risk to people
The H5N1 bird flu virus has been around for decades, and the damage it wreaks…
Backers of menthol cigarette ban vow to keep up the fight, but concede it will be a long battle
WASHINGTON — Advocates of a federal ban on menthol cigarettes have spent the better part…
Opinion: Protect the health of pregnant people and their children by including them in research
Imagine having to make this decision: Your health care provider recommends that you take a…
Opinion: The medical loss ratio has become a barrier to preventive care
Health care regulations in the United States were not designed to keep Americans healthy. The…
Expanded methadone access: giving patients greater choice
WASHINGTON — Nicholas Voyles, executive director of the Indiana Recovery Alliance, ended up missing his…
STAT+: Biden cybersecurity plan for hospitals entails carrots first, then sticks, health official says
WASHINGTON — The Biden administration’s plan to improve cybersecurity at hospitals starts off with incentives,…
STAT+: Federal judge rules against two drugmakers challenging Medicare drug price negotiation program
WASHINGTON — A federal judge in New Jersey on Monday dealt a blow to two…
STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to…
STAT+: FDA finalizes plan to regulate some lab-developed tests
The Food and Drug Administration will start actively regulating tests developed in laboratories, with some…
STAT+: Activist investor Alex Denner, Bioverativ shareholder reach tentative settlement in insider trading case
A tentative settlement has been reached in a long-running shareholder lawsuit that accused health care…
Philips will pay $1.1 billion to resolve U.S. lawsuits over breathing machines that expel debris
WASHINGTON — Medical device maker Philips said Monday it will pay $1.1 billion to settle…
STAT+: Biden administration boosts some Medicaid payments to match commercial rates
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: House bill aimed at Chinese biotechs is advancing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of…
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs…
Opinion: Medical students lose in the research arms race for residency slots
“Going to medical Spanish class really isn’t worth my time. I’d rather use the time…
STAT+: AI is becoming the exclusive province of academic medicine. A new initiative aims to change that
In Kingman, Ariz., a windswept city of 35,000 at the eastern edge of the Mojave…
There’s never a good time to drink raw milk. But now’s a really bad time as bird flu infects cows
Scientists who know about the types of pathogens — E. coli and Salmonella among them…
Opinion: Unseen battles: The harsh realities of veterans’ access to health care
I remember the day I left the military after six years of active-duty service. The…
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for…
Opinion: Déjà WTO: The WHO’s pandemic agreement shouldn’t water down intellectual property obligations
As countries resume final negotiations on Monday for a landmark pandemic agreement intended to help…
Opinion: STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more
“Former HHS secretaries: Congress should adopt site-neutral payments for health care,” by Alex Azar and…
Cattle testing for H5N1 bird flu will be more limited than USDA initially announced
New federal rules aimed at limiting the spread of the H5N1 bird flu virus among…
Biden administration punts menthol cigarette rule indefinitely
WASHINGTON — The Biden administration is walking away from a plan to permanently bar menthol cigarettes,…
STAT+: Momentum builds for House bill cracking down on Chinese biotechs
WASHINGTON — A House committee plans to mark up next month legislation that would restrict…
STAT+: Another hospital sues MultiPlan, alleging scheme to ‘suppress’ payments
MultiPlan is facing a new class action lawsuit that alleges the company and large health…
STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
And so, another working week will soon draw to a close. Not a moment too…
Opinion: True peer-to-peer conversations will improve prior authorization
It’s another busy day in my spine surgery clinic when my phone rings. Patients are…
Opinion: Solving academic medical centers’ existential crisis
Hospitals and health care systems across the United States have long been expected to provide…
Mental health crisis centers and EmPATH units: offering care that busy ERs can’t
On a spring afternoon in Tucson, Ariz., about a half dozen children and teens hung…
STAT+: Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case
After months of sustained criticism, Vertex Pharmaceuticals reached an agreement to provide a pricey cystic…
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
University of Washington professor David Baker has made a name for himself by borrowing computer…
STAT investigative series ‘Denied by AI’ wins major journalism prizes
Dear Readers, Please bear with me as I brag about two of STAT’s most accomplished…
Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread
Andrew Bowman, a veterinary epidemiologist at Ohio State University had a hunch. He had been…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Washington kicks into gear on H5N1
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT Virtual Event | Tomorrow’s Trailblazers in Science
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last…
Opinion: Shortages of generic drugs can’t be blamed solely on group purchasing organizations
The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was…
STAT+: Generative AI is supposed to save doctors from burnout. New data show it needs more training
After stratospheric levels of hype, early evidence may be bringing generative artificial intelligence down to…
Opinion: The grim reality of relocating to get access to gender-affirming care
In my work as a pediatric psychologist, I’ve been seeing a surge in the number…
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
LONDON — Claire Booth, a gene therapy researcher in London, had hoped that a biotech…
STAT+: Equity, technology, and costs top of mind for life science’s leaders
Physicians, researchers, CEOs, reporters, and more gathered in downtown Boston Wednesday night to celebrate STAT’s…
STAT+: Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
After months of deliberation, the Colombian government has issued a compulsory license for an HIV…
Spring Veggies
While most vegetables are now available year-round, May is the month gardens and farms across…